MICHAEL BROWN: Open Payments
NPI 1760746515 · MONROE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,522 in 20 payments from 13 companies in 2025. Trend: 2023 $1,004 · 2024 $943 · 2025 $1,522
Food & beverage: $1,522
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 2 | $252 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $166 |
| ABBVIE INC. | 5 | $139 |
| Neurocrine BioSciences, Inc. | 1 | $129 |
| Insulet Corporation | 1 | $124 |
| AstraZeneca Pharmaceuticals LP | 1 | $122 |
| Exact Sciences Corporation | 2 | $114 |
| Novo Nordisk Inc | 1 | $103 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $98 |
| Boston Scientific Corporation | 1 | $92 |
Products named: FREESTYLE LIBRE 3, JARDIANCE, Omnipod, BREZTRI, Ozempic, Kerendia, Intracept, EPKINLY.
Industry payments across LA — which companies pay providers there.
